PMID- 38154476
OWN - NLM
STAT- MEDLINE
DCOM- 20240101
LR  - 20240319
IS  - 1976-2437 (Electronic)
IS  - 0513-5796 (Print)
IS  - 0513-5796 (Linking)
VI  - 65
IP  - 1
DP  - 2024 Jan
TI  - Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose 
      Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review.
PG  - 19-26
LID - 10.3349/ymj.2023.0285 [doi]
AB  - PURPOSE: There are few studies in the literature on the dosage of statin that 
      equivalently reduces low-density lipoprotein cholesterol (LDL-C) compared to an 
      ezetimibe combination and whether such regimens have differences in safety. We 
      compared the lipid-modifying efficacy and safety of 5 mg rosuvastatin/10 mg 
      ezetimibe to those of 20 mg rosuvastatin. MATERIALS AND METHODS: A literature 
      search was conducted using the PubMed, EMBASE, Cochrane, Web of Sciences, and 
      SCOPUS databases up to December 2021. Human studies investigating the two 
      aforementioned regimens with a randomized controlled design were selected. 
      Outcome variables included the percentage reduction in LDL-C and other lipid 
      parameters and rates of composite adverse events (AEs), including muscle-related 
      symptoms. A random-effects meta-analysis was performed after heterogeneity 
      testing between studies. RESULTS: Seven studies were included in this 
      meta-analysis. The percentage LDL-C reduction did not differ between the 
      combination and monotherapy groups [standardized mean difference (SMD) 0.08; 95% 
      confidence interval (CI) -0.09 to 0.26; p=0.35]. The risk of composite AEs (odds 
      ratio 0.50; 95% CI 0.15 to 1.72; p=0.27) of the combination was not different 
      compared to the monotherapy group. The percentage of total cholesterol reduction 
      was greater in the combination group (SMD 0.22; p=0.02), whereas that of 
      triglyceride reduction and high-density lipoprotein cholesterol elevation did not 
      differ between the two groups. CONCLUSION: This meta-analysis showed that 5 mg 
      rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and 
      tolerability as 20 mg rosuvastatin.
CI  - (c) Copyright: Yonsei University College of Medicine 2024.
FAU - Kang, Yura
AU  - Kang Y
AUID- ORCID: 0000-0002-1961-8017
AD  - Department of Biostatistics and Computing, Graduate School of Yonsei University, 
      Seoul, Korea.
FAU - Park, Jung Mi
AU  - Park JM
AUID- ORCID: 0000-0003-1572-5832
AD  - Health Insurance Review and Assessment Service, Wonju, Korea.
FAU - Lee, Sang-Hak
AU  - Lee SH
AUID- ORCID: 0000-0002-4535-3745
AD  - Division of Cardiology, Department of Internal Medicine, Severance Hospital, 
      Yonsei University College of Medicine, Seoul, Korea. shl1106@yuhs.ac.
LA  - eng
GR  - 2022R1A2C1004946/NRF/National Research Foundation of Korea/Korea
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
RN  - EOR26LQQ24 (Ezetimibe)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
SB  - IM
MH  - Humans
MH  - Rosuvastatin Calcium/therapeutic use
MH  - Ezetimibe/adverse effects
MH  - Cholesterol, LDL/therapeutic use
MH  - *Anticholesteremic Agents/adverse effects
MH  - *Hypercholesterolemia/drug therapy
MH  - Drug Therapy, Combination
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects
MH  - Treatment Outcome
PMC - PMC10774651
OTO - NOTNLM
OT  - Hypercholesterolemia
OT  - drug therapy
OT  - hydroxymethylglutary-CoA reductase inhibitors
OT  - preventive medicine
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2023/12/29 00:42
MHDA- 2024/01/02 11:44
PMCR- 2024/01/01
CRDT- 2023/12/28 19:03
PHST- 2023/07/13 00:00 [received]
PHST- 2023/09/08 00:00 [revised]
PHST- 2023/10/05 00:00 [accepted]
PHST- 2024/01/02 11:44 [medline]
PHST- 2023/12/29 00:42 [pubmed]
PHST- 2023/12/28 19:03 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - 65.19 [pii]
AID - 10.3349/ymj.2023.0285 [doi]
PST - ppublish
SO  - Yonsei Med J. 2024 Jan;65(1):19-26. doi: 10.3349/ymj.2023.0285.